Trial Details
ENROLLING_BY_INVITATIONBasic Information
| Clinical ID | c1314 |
|---|---|
| Identifier | NCT05104723 |
| Trial Title | Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Chronic Granulomatous Disease|Inflammatory Gastrointestinal Disease|Inflammatory Skin Disease|Inflammatory Lung Disease |
| Interventions | DRUG: XELJANZ (tofacitinib) |
Participant Information
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
|---|---|
| City | Bethesda |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE1|PHASE2 |
Time Information
| Start Date | 2022-08-12 |
|---|---|
| Primary Completion Date | 2026-01-01 |
| Completion Date | 2027-01-01 |